Global progress in the fight against malaria has taken several notable turns over the past 48 hours, as new breakthroughs and milestones have been reported on both vaccine development and disease eradication fronts.
The Indian Council of Medical Research (ICMR) announced the development of AdFalciVax, a new malaria vaccine candidate that has demonstrated over 90 percent protection in mice. This vaccine leverages chimeric recombinant technology and targets two key proteins: circumsporozoite protein to prevent infection, and Pro6C protein—a fusion protein—aimed at disrupting parasite transmission through mosquitoes. Of additional significance is the vaccine’s stability at room temperature for up to nine months, a feature that could greatly simplify distribution efforts, especially in resource-limited areas. Plans for clinical trials in humans are underway, reinforcing optimism for global malaria control, according to ICMR.
In Africa, recent field advances also set the stage for new control strategies. Research published in the New England Journal of Medicine and highlighted by the Centre for Tropical Medicine and Global Health shows that mass drug administration of ivermectin, typically used for other parasitic diseases, has led to a 26 percent reduction in new malaria infections among children aged 5 to 15 in Kenyan trials. Ivermectin works by killing mosquitoes that feed on treated individuals, thus offering added protection against malaria transmission. This large-scale BOHEMIA trial, funded by Unitaid, anchors hopes for integrating ivermectin into malaria control programs, with the potential to complement vaccines and insecticide-treated nets, as highlighted by Professor Marta Maia and Dr. Joseph Mwangangi from KEMRI-Wellcome Trust.
Meanwhile, a major public health achievement was recorded in Asia. The World Health Organization officially certified Timor-Leste as malaria-free, making it the third country in the WHO South-East Asia Region to reach this milestone. The Global Fund reports that Timor-Leste had seen malaria cases reduce from over 223,000 in 2006 to zero in 2022, with no deaths since 2015. This accomplishment underscores the power of comprehensive public health strategies—combining surveillance, healthcare worker outreach, and community engagement—and offers hope to other regions struggling with malaria.
Alongside these developments, researchers continue innovating on the vaccine front. As reported by the journal MalariaWorld, multi-epitope vaccine candidates targeting different blood stages of the malaria parasite are being designed using advanced immunoinformatics approaches. Such strategies are expected to further minimize resistance and offer long-term immunity.
Additional momentum is seen through collaborations aiming to reduce costs and improve accessibility of next-generation malaria interventions. BioProcess International notes that Eyam and the Medicines for Malaria Venture have joined forces to develop a $1 malaria shot using monoclonal antibodies and AI-driven optimization, potentially ushering in a new era of affordable protection.
Taken together, these advances mark an important period in the campaign against malaria: from a promising new vaccine in India showing robust early results, to innovative drug trials and the formal recognition of Timor-Leste’s elimination of malaria, global actors continue to push the boundaries of science and policy in the ongoing quest for eradication.
This content was created in partnership and with the help of Artificial Intelligence AI
The Indian Council of Medical Research (ICMR) announced the development of AdFalciVax, a new malaria vaccine candidate that has demonstrated over 90 percent protection in mice. This vaccine leverages chimeric recombinant technology and targets two key proteins: circumsporozoite protein to prevent infection, and Pro6C protein—a fusion protein—aimed at disrupting parasite transmission through mosquitoes. Of additional significance is the vaccine’s stability at room temperature for up to nine months, a feature that could greatly simplify distribution efforts, especially in resource-limited areas. Plans for clinical trials in humans are underway, reinforcing optimism for global malaria control, according to ICMR.
In Africa, recent field advances also set the stage for new control strategies. Research published in the New England Journal of Medicine and highlighted by the Centre for Tropical Medicine and Global Health shows that mass drug administration of ivermectin, typically used for other parasitic diseases, has led to a 26 percent reduction in new malaria infections among children aged 5 to 15 in Kenyan trials. Ivermectin works by killing mosquitoes that feed on treated individuals, thus offering added protection against malaria transmission. This large-scale BOHEMIA trial, funded by Unitaid, anchors hopes for integrating ivermectin into malaria control programs, with the potential to complement vaccines and insecticide-treated nets, as highlighted by Professor Marta Maia and Dr. Joseph Mwangangi from KEMRI-Wellcome Trust.
Meanwhile, a major public health achievement was recorded in Asia. The World Health Organization officially certified Timor-Leste as malaria-free, making it the third country in the WHO South-East Asia Region to reach this milestone. The Global Fund reports that Timor-Leste had seen malaria cases reduce from over 223,000 in 2006 to zero in 2022, with no deaths since 2015. This accomplishment underscores the power of comprehensive public health strategies—combining surveillance, healthcare worker outreach, and community engagement—and offers hope to other regions struggling with malaria.
Alongside these developments, researchers continue innovating on the vaccine front. As reported by the journal MalariaWorld, multi-epitope vaccine candidates targeting different blood stages of the malaria parasite are being designed using advanced immunoinformatics approaches. Such strategies are expected to further minimize resistance and offer long-term immunity.
Additional momentum is seen through collaborations aiming to reduce costs and improve accessibility of next-generation malaria interventions. BioProcess International notes that Eyam and the Medicines for Malaria Venture have joined forces to develop a $1 malaria shot using monoclonal antibodies and AI-driven optimization, potentially ushering in a new era of affordable protection.
Taken together, these advances mark an important period in the campaign against malaria: from a promising new vaccine in India showing robust early results, to innovative drug trials and the formal recognition of Timor-Leste’s elimination of malaria, global actors continue to push the boundaries of science and policy in the ongoing quest for eradication.
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Global progress in the fight against malaria has taken several
notable turns over the past forty eight hours, as new
breakthroughs and milestones have been reported on both vaccine development
and disease eradication fronts. The Indian Council of Medical Research
ICMR announced the development of ad falcyvax, a new malaria
(00:20):
vaccine candidate that has demonstrated over ninety per cent protection
in mice. This vaccine leverages chimeric recombinant technology and targets
two key proteins, circumsporozoit protein to prevent infection and pro
six C protein, a fusion protein aimed at disrupting parasite
transmission through mosquitoes. Of additional significance is the vaccine's stability
(00:43):
at room temperature for up to nine months, a feature
that could greatly simplify distribution efforts, especially in resource limited areas.
Plans for clinical trials in humans are underway, reinforcing optimism
for global malaria control according to ICMR. In Africa, recent
field advances also set the stage for new control strategies.
(01:06):
Research published in the New England Journal of Medicine and
highlighted by the Center for Tropical Medicine and Global Health
shows that mass drug administration of ivermectin, typically used for
other parasitic diseases, has led to a twenty six per
cent reduction in new malaria infections among children aged five
to fifteen in Kenyan trials. Ivermectin works by killing mosquitoes
(01:29):
that feed on treated individuals, thus offering added protection against
malaria transmission. This large scale Bohemia trial, funded by UNITAID anchors,
hopes for integrating ivermectin into malaria control programs, with the
potential to complement vaccines and insecticide treated nets, as highlighted
by Professor Martemaya and doctor Joseph Mongangi from Chemery Welcome Trust. Meanwhile,
(01:53):
a major public health achievement was recorded in Asia. The
World Health Organization officially certified tim Or Lesste as malaria free,
making it the third country in the WHO Southeast Asia
region to reach this milestone. The Global Fund reports that
tim Or Leste had seen malaria cases reduce from over
two hundred twenty three thousand in two thousand six to
(02:14):
zero in twenty twenty two, with no deaths since twenty fifteen.
This accomplishment underscores the power of comprehensive public health strategies
combining surveillance, healthcare worker outreach, and community engagement, and offers
hope to other regions struggling with malaria. Alongside these developments,
researchers continue innovating on the vaccine front. As reported by
(02:39):
the journal Malaria World, multi epitope vaccine candidates targeting different
blood stages of the malaria parasite are being designed using
advanced immunoinformatics approaches. Such strategies are expected to further minimize
resistance and offer long term immunity. Additional momentum is seen
through collaborations aiming to reduce costs and improve accessibility of
(03:01):
next generation malaria interventions. Bioprocess International notes that i AM
and the Medicines for Malaria Venture have joined forces to
develop a one dollar malaria shot using monoclonal antibodies and
AI driven optimization, potentially ushering in a new era of
affordable protection. Taken together, these advances mark an important period
(03:24):
in the campaign against malaria. From a promising new vaccine
in India showing robust early results, to innovative drug trials
and the formal recognition of tiam Or Leste's elimination of malaria.
Global actors continue to push the boundaries of science and
policy in the ongoing quest for eradication
Global progress in the fight against malaria has taken several
notable turns over the past forty eight hours, as new
breakthroughs and milestones have been reported on both vaccine development
and disease eradication fronts. The Indian Council of Medical Research
ICMR announced the development of ad falcyvax, a new malaria
(00:20):
vaccine candidate that has demonstrated over ninety per cent protection
in mice. This vaccine leverages chimeric recombinant technology and targets
two key proteins, circumsporozoit protein to prevent infection and pro
six C protein, a fusion protein aimed at disrupting parasite
transmission through mosquitoes. Of additional significance is the vaccine's stability
(00:43):
at room temperature for up to nine months, a feature
that could greatly simplify distribution efforts, especially in resource limited areas.
Plans for clinical trials in humans are underway, reinforcing optimism
for global malaria control according to ICMR. In Africa, recent
field advances also set the stage for new control strategies.
(01:06):
Research published in the New England Journal of Medicine and
highlighted by the Center for Tropical Medicine and Global Health
shows that mass drug administration of ivermectin, typically used for
other parasitic diseases, has led to a twenty six per
cent reduction in new malaria infections among children aged five
to fifteen in Kenyan trials. Ivermectin works by killing mosquitoes
(01:29):
that feed on treated individuals, thus offering added protection against
malaria transmission. This large scale Bohemia trial, funded by UNITAID anchors,
hopes for integrating ivermectin into malaria control programs, with the
potential to complement vaccines and insecticide treated nets, as highlighted
by Professor Martemaya and doctor Joseph Mongangi from Chemery Welcome Trust. Meanwhile,
(01:53):
a major public health achievement was recorded in Asia. The
World Health Organization officially certified tim Or Lesste as malaria free,
making it the third country in the WHO Southeast Asia
region to reach this milestone. The Global Fund reports that
tim Or Leste had seen malaria cases reduce from over
two hundred twenty three thousand in two thousand six to
(02:14):
zero in twenty twenty two, with no deaths since twenty fifteen.
This accomplishment underscores the power of comprehensive public health strategies
combining surveillance, healthcare worker outreach, and community engagement, and offers
hope to other regions struggling with malaria. Alongside these developments,
researchers continue innovating on the vaccine front. As reported by
(02:39):
the journal Malaria World, multi epitope vaccine candidates targeting different
blood stages of the malaria parasite are being designed using
advanced immunoinformatics approaches. Such strategies are expected to further minimize
resistance and offer long term immunity. Additional momentum is seen
through collaborations aiming to reduce costs and improve accessibility of
(03:01):
next generation malaria interventions. Bioprocess International notes that i AM
and the Medicines for Malaria Venture have joined forces to
develop a one dollar malaria shot using monoclonal antibodies and
AI driven optimization, potentially ushering in a new era of
affordable protection. Taken together, these advances mark an important period
(03:24):
in the campaign against malaria. From a promising new vaccine
in India showing robust early results, to innovative drug trials
and the formal recognition of tiam Or Leste's elimination of malaria.
Global actors continue to push the boundaries of science and
policy in the ongoing quest for eradication
Popular Podcasts
On Purpose with Jay Shetty
I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.